STOCKS TELEGRAPH

Tag: OTC:ENZC

  • Stock that deserve a closer look under the hood: Enzolytics Inc [ENZC]

     

    When viewed in terms of performance, the ENZC performance for the week was 37.63% while its performance for the month was 44.25%. The quarterly performance of Enzolytics, Inc. (OTC PINK:ENZC) saw a decline of -1.17%, and 9.94% for the last six months. In the last 52 weeks, the stock’s price range has been $0.0047–$0.9580. Nothing new appeared in the publications about the stock. In fact, the most recent news about the stock was almost 2 months ago.

    Most Recent News

    On July 29, 2021, ENZC revealed that an agreement was reached with Danhson and Clinic Design to advance Enzolytics’ anti-HIV therapeutic ITV-1 into production and clinical trials. Prior to approval by the European Medicines Agency (EMA), these steps were necessary.

    It was revealed in an announcement that the Clinical trials will be conducted at Clinic Design after production of the therapeutic is completed at Danhson pharmaceutical company facilities. Then the production of the therapeutics will be completed followed by clinical trials. In this trial, Pharmalex, an EU regulatory consulting firm, will be in charge of developing the protocol.

    July 26, 2020– Enzolytics, Inc. (OTC PINK:ENZC) announced Steve Sharabura has been appointed as President of its Atlanta-based wholly-owned subsidiary RobustoMed, Inc. The Atlanta-based subsidiary was to develop a new business model focused on establishing international partnerships with drug development companies. The focus of Mr. Sharabura’s work was on expanding revenue and partnerships in key markets globally, including Brazil, Costa Rica, and other emerging markets.

    Canadian native Mr. Sharabura also has international experience. A key United Nations agency relied on him for technology expansion. An emerging technology worth $10m plus has been sold to major telecommunications firms by him. Steve has worked in various technology fields for over 30 years, both with small entrepreneurial companies and large multinational corporations. In the past, he has improved company productivity across a wide range of fields.

    The MBA he earned at Cornell University is combined with an undergraduate degree in economics from the University of Western Ontario.

    What do they do at ENZC?

    ENZC develops proprietary antibiotics that treat debilitating infectious diseases. We have patented HIV therapeutics and a proprietary method for producing human IgG1 monoclonal antibodies to treat infectious diseases without causing any harm to humans. Our HIV therapeutics have undergone clinical testing. The company has also created a proprietary cell line that can produce human monoclonal antibodies that neutralize HIV. The company is based in Plano, Texas.

  • What Happened Last Session To Make Enzolytics (ENZC) Stock Drop?

    What Happened Last Session To Make Enzolytics (ENZC) Stock Drop?

    After dropping -2.38% in the last session, Enzolytics Inc (OTCPINK: ENZC) closed the last session at $0.2010, bringing its market cap to $562.39M. Enzolytics stock recently traded 42.22M shares, higher than the average daily volume of 41.93M. In addition, the shares have traded between $0.1821 and $0.2289. There are 2.80 billion outstanding shares compared to a float of 1.88 billion.

    As measured by performance, ENZC stock performed -27.44% last week and 57.40% last month. While the quarterly performance fell by 33.07 percent, the annual performance improved by 51.85 percent with a 215.05% six-month performance. ENZC stock prices ranged from $0.0002 – $0.9580 in the past 52 weeks. Despite announcing progress in clinical trials, ENZC stock dropped.

    What was the purpose of those clinical trials?

    Enzolytics is a pharmaceutical company dedicated to the development and commercialization of proprietary proteins and monoclonal antibodies to treat disease caused by debilitating infectious agents. A number of therapeutics are being developed by ENZC for the treatment of infectious diseases. Among the ENZC’s patented and clinically tested compounds, ITV-1 (Immune Therapeutic Vaccine-1) contains l-inactivated pepsin fraction (IPF) that has been shown effective in treating HIV/AIDS.

    A strategy by Enzolytics to advance its previously tested anti-HIV therapeutic ITV-1 to clinical trials and widespread distribution in Europe has been finalized.

    • ENZC will achieve a significant milestone for both human health and profitability when these steps are completed for its anti-HIV therapy.
    • An anti-HIV therapeutic developed by ENZC earlier made progress toward Bulgarian Drug Agency (BDA) certification, however that process was interrupted before it was completed.
    • A significant number of positive results from clinical trials were nevertheless documented during that period.
    • ENZC has no doubt that the clinical trials under the European Medicines Agency (EMA) will similarly succeed as a result of these positive results

    How ENZC will go through it?

    International Medical Partners Ltd. (IMPL) was formed by Enzolytics (ENZC) and European-based partners. IMPL is owned equally by ENZC and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency including Russia and its ex-Soviet states.

    For the initial production of ITV-1, ENZC engages Danhson Ltd., a Contract Manufacturing Company (CMO) for use in preparing the Best Methods Report for future production and clinical trial documentation.

  • Did Anything Hurt Enzolytics (ENZC) Stock Last Trading?

    Did Anything Hurt Enzolytics (ENZC) Stock Last Trading?

    The stock of Enzolytics Inc (OTCPink: ENZC) closed down -3.01% to $0.1160 in the last trading session. A total of 13.98M shares exchanged hands during the session, with the price of Enzolytics stock ranging from $0.1140 to $0.1220. ENZC stock dropped despite the discovery of new target sites on HTLV-1 that was announced yesterday.

    In what way did that discovery occur?

    In addition to developing proprietary medicines to treat debilitating infectious diseases, Enzolytics is committed to commercializing its products worldwide. ITV-1 is ENZC’s patented treatment for HIV/AIDS, which uses inactivated pepsin fraction (IPF) as a suspension. Additionally, ENZC is the only company developing a proprietary technology for producing monoclonal antibodies (mAbs) for treating infectious diseases like HIV, rabies, influenza A, influenza B, tetanus, and diphtheria.

    In an industry first, Enzolytics revealed yesterday that it has identified conserved, immutable sites on the HTLV-1 virus that it is targeting with monoclonal antibodies (mAbs).

    • The HTLV-1 virus is not a vaccine target, nor are there current antiviral drugs that are effective against the virus.
    • A conserved target site has now been identified using ENZC’s proprietary Artificial Intelligence (AI) methodology.
    • At the Institute for Preclinical Studies at Texas A&M University, ENZC plans to manufacture human monoclonal antibodies against these target sites.
    • A team from ENZC is attempting to identify critical sites on viruses that monoclonal antibodies will target to treat infectious viral diseases using Artificial Intelligence.
    • Multi-targeted monoclonal antibodies targeting a range of conserved sites are crucial for an effective treatment strategy according to ENZC’s experts.
    • EnZC is thus able to administer a “cocktail” of antibodies aimed at conserved and expectedly immutable targets.

    How will ENZC excel in the future?

    ENZC has now developed a comprehensive platform to produce numerous monoclonal antibodies targeting various pathogens. In ENZC’s platform, multiple conserved and expected to remain immutable sites on viruses are first identified and then fully human monoclonal antibodies that target those sites are produced. By using this approach, Enzolytics (ENZC) can tackle innumerable infectious diseases in humans with new and durable treatments.